AccurKardia brings ECG Software to Lucem Health’s AI platform

AccurKardia, a pioneering ECG-led diagnostics software company, has recently announced a strategic partnership with Lucem Health, a leading provider of clinical AI solutions, marking the beginning of a multi-year agreement.

As part of this collaboration, AccurKardia will integrate its FDA-cleared ECG interpretation software platform, known as AccurECG, into Lucem Health's Reveal family of solutions. The primary focus of these solutions is to identify individuals who may be at an elevated risk of severe or chronic diseases, providing clinicians with valuable insights for proactive healthcare.

AccurECG is a cloud-based, device-agnostic, and fully automated ECG interpretation software platform capable of detecting up to 13 arrhythmias. By integrating this advanced technology, the partnership aims to streamline the ECG review process for clinicians, facilitating prompt and effective treatment for patients dealing with cardiovascular diseases.

Juan C. Jiménez, CEO of AccurKardia, expressed the significance of this collaboration, stating, "This is an important step in our mission to improve patients’ outcomes and save lives at scale. Our software helps clinicians review ECGs more efficiently and enables prompt treatment of patients, with key cardiovascular insights delivered in minutes."

Lucem Health’s Reveal solutions, designed to uncover potential health risks that may not be immediately apparent, complement AccurECG's capabilities. The synergy between the two companies is expected to enhance the efficiency of clinicians, offering a comprehensive approach to patient care.

The partnership anticipates unveiling their first product incorporating AccurKardia’s FDA-cleared technology later this year. This collaborative effort signifies a promising advancement in leveraging advanced ECG interpretation and clinical AI to enhance patient outcomes and contribute to the evolution of healthcare diagnostics.